Topics covered: NIH Budget Uncertainty, Health Care Consolidation Activity, Cost Reduction and Improving Efficiencies, Chinese CRO Growth
Companies covered: Neostem, Inc. (NASDAQ:NBS), NanoViricides, Inc. (NYSEAMERICAN:NNVC), Albany Molecular Research, Inc. (NASDAQ:AMRI), Thermo Fisher Scientific Inc (NYSE:TMO), Medtronic, Inc. (NYSE:MDT), Life Technologies Corporation, Illumina, Inc. (NASDAQ:ILMN), Hologic, Inc. (NASDAQ:HOLX), Edwards Lifesciences Corporation (NYSE:EW), Agilent Technologies, Inc. (NYSE:A), CEPHEID (NASDAQ:CPHD), Danaher Corporation (NYSE:DHR), Amazon.com, Inc. (NASDAQ:AMZN), Wuxi Pharmatech (Cayman) Inc. (NYSE:WX), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), 3SBio Inc., Mindray Medical International Limited (NYSE:MR), Enzo Biochem, Inc. (NYSE:ENZ), Cleveland BioLabs, Inc. (NASDAQ:CBLI), Amgen Inc. (NASDAQ:AMGN)
